Arcturus Therapeutics (ARCT) Misses Q1 EPS by 411c
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Join SI Premium – FREE
Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($0.52), $4.11 worse than the analyst estimate of $3.59. Revenue for the quarter came in at $29.38 million versus the consensus estimate of $205.21 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Starts Holley (HLLY) at Buy
- Faraday Future signs cooperation deals for Middle East robotics push
- NextNRG secures $1M merchant cash advance from Avanza Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
